Phone-read urine tests and a nurse team for diabetic kidney checks
TL;DR Kidneydip posts a urine strip kit every few months to people with diabetes or high blood pressure. They photograph the strip, the app reads it, and a nurse calls when a result looks off and alerts their doctor. Clinics, insurers and employers pay, because catching kidney damage early is cheaper than treating failure.
India has about 101 million adults with diabetes[1], and diabetes and hypertension are the two main roads into chronic kidney disease. How common that disease already is depends on the study you pick - 7.5% in a 2015 Delhi and Chennai survey[2] and 13.24% in a 2025 national review by JIPMER[3]. They used different methods and years, so check both or ask a nephrologist.
Kidney damage leaks albumin into urine years before any symptoms show up. The test for it is cheap, but it means a separate lab trip, a bill and lost work, so a lot of diabetic patients skip it until the damage is advanced and the cheap options are gone.
Smart toilets were meant to fix this. The ones on sale fit western bowls, cost about ₹37,900 (€349.95) and don't even measure albumin[4].
What it does, in regulatory terms: monitoring and triage for already-diagnosed patients. Kidneydip does not diagnose kidney disease or change treatment. A lab test and a doctor confirm every flag. The app that reads the strip is probably regulated diagnostic software, likely Class B under CDSCO's 2026 software guidance[5], so the first version uses strips from a maker that already holds a CDSCO licence.
Here's how it works - a doctor or insurer enrols the patient and a kit arrives every three months. The patient dips the strip, lays it on a colour card and takes a photo. Computer vision reads albumin, creatinine, protein and glucose, corrects for poor light and rejects blurry shots. Readings from the patient's own BP monitor and glucometer go into the same record. A nurse reviews every abnormal result within two working days, calls the patient and sends the doctor a suggested lab test.
The seed pictured a toilet that tests urine passively. That doesn't fit India, because squat toilets dominate many Indian homes[6] and the current devices are wellness gadgets. A scheduled strip with a human behind it reaches far more people.
The patient is usually over 40, already diagnosed, and owns a smartphone or has a child who does. Diabetologists and diabetes clinic chains are the first channel, since they want better follow-up and some will charge for it. One Indian phone-read test maker already sells urine cards to about 4,000 doctors[7], with retail kits at ₹249[8]. My rough estimate is a ₹400–900 monthly subscription covering kits and the nurse team. Insurers and employers are the bigger payers later, once there's Indian outcome data.
Phone-read albumin tests are now credible, and one smartphone kidney test won FDA clearance in July 2022[9]. An Indian rival raised ₹16.6 Cr in February 2024 to sell its version in India[7]. CDSCO issued final guidance on medical device software in July 2026[5], and more than 93 crore ABHA IDs exist for results to flow into[10].
There's no public figure for home kidney monitoring in India. The closest is urinalysis overall, which one market research firm puts at US$112.2M in 2024, about ₹1,085 Cr, and 85.83% of that is consumables such as strips[11]. Home testing is an unknown slice of it.
The better sum is bottom-up - 101 million diabetic adults[1], times the share whose doctors would prescribe home checks, times the monthly fee. That share is untested.
The FDA-cleared smartphone kidney test is the one to study, with a payer-led rollout through the NHS and US insurers rather than shops[13]. A Mumbai startup sells phone-read urine cards to doctors and pharmacies[7] and could be your supplier and your rival at once. Smart toilet sensors from big consumer-health and bathroom brands sit in western toilets and sell as wellness devices[4].
Nobody in India yet sells scheduled testing plus a nurse team on a subscription.
| Difficulty | Moderate (49/100) |
| Starting capital | ₹1.8–3.1 Cr |
| Time to launch | 9–15 months |
Regulation is the hardest part. You need a licensed strip partner, a study proving home and lab results agree and a clear answer on the app's device class before you write much code. Reading strips across cheap phones and bad lighting is real computer vision work. Selling is slow too, since doctors refer one patient at a time.
Yes, because the strip and the app that reads it are both likely regulated diagnostics.
Building this outside India? The categories above usually have a local equivalent, so check with your own regulator.
Don't let AI diagnose kidney disease or change treatment. Every flag goes to a nurse and a lab test, and the doctor decides.
Want to work out the AI layer for Kidneydip? Talk to Yash →
I think a nurse-backed service built on phone-read strips is a sensible business, and a passive smart toilet for Indian homes is not ready. This suits a founder with ties to diabetologists or insurers who can run a clinical operations team. If you want to build hardware then skip it. Prove first that home and lab results agree on at least 30 paired tests.
My estimate is ₹1.8–3.1 Cr to launch, covering the app, licensed strips, a nurse team and early doctor and insurer partnerships. The kit breaks it down line by line.
Yes. Urine strips are regulated diagnostics, likely Class B, and the app that reads them probably is too, so start with strips that already hold a CDSCO licence.
Yes, and smartphone urinalysis has already been cleared abroad. Check how your own regulator classifies the strip and the app.
The free Kidneydip validation kit has the line-by-line capital breakdown, the effort scoring, the CDSCO and data-protection checklist, a 14-day validation sprint with pass/fail targets, a 90-day launch plan, 10 interview questions for doctors and patients, and 5 assumptions to test. Download the kit →
Thinking of building Kidneydip or something like it? The make-or-break bit is settling the app's device class and running a home-versus-lab accuracy study that doctors will trust, and that's the kind of thing I help founders with. If you need a hand, you know where to find me. Talk to Yash →
For illustration only. Names are fictional and ideas hypothetical; sourced facts are real but may be out of date. Nothing here is legal, financial or professional advice, and Yash Khatri is not personally liable for any use of it. Read the full disclaimer.